Surgical Management of Spasticity in Children (Botulinum Toxin, Phenol, Intrathecal Baclofen, Selective Dorsal Rhizotomy)

Status: draft · Last updated 2026-11-16 · By Jason S. Hauptman, MD, PhD (AI-assisted)

Read in the interactive book →

High-yield points

  • SDR:
    • Evidence: RCT-proven to reduce spasticity, with a small functional gain (GMFM +4) .
    • Best candidate: the young ambulatory child with pure spastic diplegia .
    • Later course: spine and orthopedic problems mostly follow CP's natural history .
  • ITB:
    • Best candidate: severe generalized spasticity or dystonia, GMFCS IV–V; it beat placebo in dyskinetic CP .
    • Complications: expect them in most patients, mainly catheter problems and pseudomeningocele .
  • ITB test dose: a 50-μg bolus (25 μg in small children), but it is not always necessary .
  • BoNT-A:
    • Effect: a modest, time-limited tone reduction (about 12 weeks) .
    • Safety: systemic adverse events about 1%, highest at GMFCS IV–V and higher doses .
  • Phenol gives months-long obturator nerve blocks for adductor tone .

Landmark papers

  • McLaughlin et al., Dev Med Child Neurol 2002: meta-analysis of three randomized trials of selective dorsal rhizotomy (90 children). GMFM improved more by +4.0 (P = .008), with benefit rising with the percentage of root tissue cut .
  • IDYS (Bonouvrié et al., Ann Neurol 2019): randomized placebo-controlled trial of intrathecal baclofen in dyskinetic cerebral palsy. Goal attainment (GAS T-score) was 38.9 vs 21.0 (P < .001) .

Spasticity in children, mostly from cerebral palsy (CP), is treated on a ladder: therapy and orthoses, oral drugs, focal chemodenervation, then neurosurgery. Each step is matched to the distribution of tone (focal or generalized), its type (pure spasticity or mixed with dystonia), and the child's Gross Motor Function Classification System (GMFCS) level and goals.

Jason S. Hauptman, MD, PhD© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure from Hauptman's High Yield Thoughts in Pediatric Neurosurgery (pedsneurosurg.org). Do not copy, reproduce, redistribute or adapt without written permission.https://www.pedsneurosurg.org/hy-peds-ns:spasticity_procedures:472dd764d6e70ca2© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure; please do not copy, reproduce or redistribute without written permission.Single-level selective dorsal rhizotomy at the conus with dorsal roots separated from ventral roots, rootlets stimulated under EMG and some sectioned; and an intrathecal baclofen pump in a subfascial abdominal pocket with a catheter tunneled to a lumbar entry and its tip in the lower thoracic subarachnoid space(A) SELECTIVE DORSAL RHIZOTOMY, SINGLE-LEVEL (POSTERIOR VIEW, CRANIAL UP)T11T12L2conus medullaris(under the L1 laminectomy)dura openedsectioned rootletsEMG-guided stimulation(electrode on a rootlet)dorsal roots (sensory)L2–S1ventral roots (motor)beneath the separator cardrootlets(B) INTRATHECAL BACLOFEN PUMP (OBLIQUE-LATERAL TORSO, ANTERIOR LEFT)T9T10T11T12L1L2L3L4L5intrathecal catheter tipT10–T12 for lower-limb spasticity;higher (e.g., C5–T2) forupper-limb spasticity / dystonialumbar insertiontunneled catheterpump (subfascial)schematic; not to scale
Spasticity procedures. (a) Selective dorsal rhizotomy through a single-level laminectomy at the conus: dorsal (sensory) roots separated from ventral (motor) roots, divided into rootlets, tested with EMG-guided stimulation and partly sectioned. (b) Intrathecal baclofen: a programmable pump in a subfascial abdominal pocket, with a tunneled catheter entering the lumbar thecal sac and its tip in the thoracic subarachnoid space. Original schematic.

Workup for every candidate

Botulinum toxin A (BoNT-A)

Phenol neurolysis

Intrathecal baclofen (ITB)

Selective dorsal rhizotomy (SDR)

SDR complications and spine

Choosing among them

Related topics

References

  1. Novak I, Morgan C, Fahey M, et al. State of the evidence traffic lights 2019: systematic review of interventions for preventing and treating children with cerebral palsy. Curr Neurol Neurosci Rep 2020;20(2):3. doi:10.1007/s11910-020-1022-z. PMID 32086598. verified
  2. Tu A, Steinbok P. Long term outcome of selective dorsal rhizotomy for the management of childhood spasticity—functional improvement and complications. Childs Nerv Syst 2020;36(9):1985–1994. doi:10.1007/s00381-020-04747-8. PMID 32577879. verified
  3. McLaughlin J, Bjornson K, Temkin N, et al. Selective dorsal rhizotomy: meta-analysis of three randomized controlled trials. Dev Med Child Neurol 2002;44(1):17–25. doi:10.1017/s0012162201001608. PMID 11811645. verified
  4. Retkowska-Tomaszewska N, Defort P, Barciszewska AM, et al. Intrathecal baclofen in children with cerebral palsy: a critical review of selection criteria, rehabilitation goals, outcomes, and complications. J Clin Med 2026;15(11):4091. doi:10.3390/jcm15114091. PMID 42278952. verified
  5. Alghadier M, Alsuwayegh A. Efficacy of botulinum toxin type A for spasticity management and motor function in children with cerebral palsy: a systematic review and meta-analysis of randomized controlled trials. Front Neurol 2026;17:1751493. doi:10.3389/fneur.2026.1751493. PMID 41809197. verified
  6. Naidu K, Smith K, Sheedy M, et al. Systemic adverse events following botulinum toxin A therapy in children with cerebral palsy. Dev Med Child Neurol 2010;52(2):139–144. doi:10.1111/j.1469-8749.2009.03583.x. PMID 20412252. verified
  7. Kwon JY, Kim JS. Selective blocking of the anterior branch of the obturator nerve in children with cerebral palsy. Am J Phys Med Rehabil 2009;88(1):7–13. doi:10.1097/PHM.0b013e31815b6381. PMID 17993980. verified
  8. Bonouvrié LA, Becher JG, Vles JSH, et al. The effect of intrathecal baclofen in dyskinetic cerebral palsy: the IDYS trial. Ann Neurol 2019;86(1):79–90. doi:10.1002/ana.25498. PMID 31050023. verified
  9. Boster AL, Bennett SE, Bilsky GS, et al. Best practices for intrathecal baclofen therapy: screening test. Neuromodulation 2016;19(6):616–622. doi:10.1111/ner.12437. PMID 27434115. verified
  10. Abdelmageed S, Horak VJ, Mossner J, et al. Safety and efficacy of intrathecal baclofen trials for the treatment of hypertonia: a retrospective cohort study. J Neurosurg Pediatr 2024;33(2):179–184. doi:10.3171/2023.11.PEDS23473. PMID 38064708. verified
  11. Ryan MV, Freeman LM, Blasco S, et al. Complications of intrathecal baclofen therapy in children and young adults. J Neurosurg Pediatr 2024;34(6):659–670. doi:10.3171/2024.6.PEDS23360. PMID 39303297. verified
  12. Grunt S, Fieggen AG, Vermeulen RJ, et al. Selection criteria for selective dorsal rhizotomy in children with spastic cerebral palsy: a systematic review of the literature. Dev Med Child Neurol 2014;56(4):302–312. doi:10.1111/dmcn.12277. PMID 24106928. verified
  13. Park TS, Liu JL, Edwards C, et al. Functional outcomes of childhood selective dorsal rhizotomy 20 to 28 years later. Cureus 2017;9(5):e1256. doi:10.7759/cureus.1256. PMID 28649479. verified
  14. O'Brien DF, Park TS, Puglisi JA, et al. Effect of selective dorsal rhizotomy on need for orthopedic surgery for spastic quadriplegic cerebral palsy: long-term outcome analysis in relation to age. J Neurosurg 2004;101(1 Suppl):59–63. doi:10.3171/ped.2004.101.2.0059. PMID 16206973. verified
  15. Golan JD, Hall JA, O'Gorman G, et al. Spinal deformities following selective dorsal rhizotomy. J Neurosurg 2007;106(6 Suppl):441–449. doi:10.3171/ped.2007.106.6.441. PMID 17566400. verified
  16. Miller SD, Lewis E, Lau J, et al. The effect of selective dorsal rhizotomy on scoliosis in children with cerebral palsy: a long-term follow-up study. J Pediatr Orthop 2025;45(3):158–163. doi:10.1097/BPO.0000000000002878. PMID 39636007. verified

Verification (2026-11-16):

Caveats: